CLNN - Clene adds 16% after new data for lead asset in ALS study
2023-03-09 07:15:02 ET
- Clene Inc. ( NASDAQ: CLNN ) shares gained ~16% pre-market Thursday in reaction to new results from its HEALEY ALS Platform Trial for lead candidate CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS), a rare neurological disease.
- Based on exploratory analyses of certain prespecified endpoints, the company said CNM-Au8 was linked to a 74% lower risk of ALS clinical worsening (p = 0.035) after 24 weeks of therapy at 30mg.
- Other encouraging findings include a 98% lower risk of death or permanent assisted ventilation (p= 0.028) and a 95% lower risk of death (p= 0.053).
- The company expects to share the data with the FDA at a future end-of-Phase 2 meeting.
- “When supported by a confirmatory trial, this would give people living with ALS longer periods of independence, which are precious to them and their families,” Clene ( CLNN ) Chief Executive Rob Etherington remarked.
- Clene ( CLNN ) shares crashed in October after the company said CNM-Au8 did not reach the primary endpoint in the HEALEY ALS trial.
For further details see:
Clene adds 16% after new data for lead asset in ALS study